ContraVir Pharmaceuticals, Inc. (OTCQB:CTRV) is a biopharmaceutical company focused on the discovery and development of targeted antiviral therapies. The company’s leading candidate, FV-100, is being developed for the treatment of shingles. Preclinical studies have demonstrated FV-100 as a significant improvement in potency as compared to currently available FDA-approved drugs. The company is planning a large trial to explore FV-100’s potential to treat long-term nerve pain typically associated with shingles. For more information, visit the company’s website at www.contravir.com.

Noble Financial Capital Markets, an equity research driven, full-service, investment banking boutique, is hosting its tenth annual equity conference in Sandpiper Bay, FL. Attended by institutional investors from across North America, the event features more than 140 public company executive teams from a diverse range of industries. For more information, visit www.noble.missionir.com.